Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Lingvay I, Sumithran P, le Roux CW, Cohen RV
Supporting this, in a phase 2a trial in people with MASLD, the dual GLP-1/GCG agonist efinopegdutide (10 mg) reduced liver fat by 72.7%, compared to 42.3% with semaglutide (1 mg) despite similar WLindicating potential weight-independent effects of GCG on hepatic steatosis [40]
GLP-1 Receptor Activation: Suppresses appetite through hypothalamic pathways Slows gastric emptying Enhances insulin secretion GIP Receptor Activation: Amplifies GLP-1 satiety effects Improves insulin sensitivity May directly affect fat cell metabolism Glucagon Receptor Activation: Increases energy expenditure (metabolic rate) Promotes fat breakdown (lipolysis) May prevent metabolic adaptation The Advantage: Single molecule means simpler manufacturing, potentially easier regulatory approval, and all three pathways activated with every dose
Estimula el crecimiento de nuevos vasos sanguneos y el suministro de nutrientes a los tejidos daados
Consult a healthcare professional for any advice if pregnancy is suspected
